

Indicator development programme

Equality Impact Assessment

IND247 Atrial fibrillation: DOACs and vitamin K antagonists

1. Have any potential equality issues been identified during the development process?

No.

2. Have any population groups, treatments or settings been excluded from coverage by the indicator? Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

People with a CHA₂DS₂-VASc score of less than 2 are not included in the indicator. This exclusion is justified as in line with the strength of the recommendation on anticoagulation for people with a risk score less than 2 (NICE NG196 1.6.4).

3. Does the indicator make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

4. Is there potential for the indicator to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

Completed by NICE quality assurance lead: Craig Grime

Date: 09.11.22